This study will assess the efficacy of an innovative point of service cancer genetics counseling delivery model for metastatic breast cancer (MBC) patients whom have received a referral for hereditary cancer genetic counseling and testing.
Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent. Able to speak and read in the English language. Have a diagnosis of human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer. Participants must be enrolled in the parent registry study.
Exclusion Criteria:
Genetic testing for a breast cancer gene (BRCA) BRCA1 and BRCA2 mutation completed after 2013 or any BRCA 1 and BRCA2 testing with large rearrangement testing. Prior genetic counseling is allowed. Psychiatric illness/social situations that would limit compliance with study requirements.
